

Welcome to this Horizon funding webinar

Housekeeping



Please note that this session is being recorded.
By remaining in the meeting, you are consenting to it being recorded



Please, enable your camera.



Please, mute your microphone during the presentation. Use the chat box to communicate questions and comments for a discussion later.

Welcome to this Horizon funding webinar

> 11 June 2021: HOW CAN EATRIS SUPPORT YOUR FUNDING PROPOSAL?

Anne-Charlotte Fauvel
EATRIS Head of European Affairs
annecharlottefauvel@eatris.eu



Next EATRIS Horizon funding webinars



- > 25 June 2021 – “Optimising the innovation and exploitation strategies of your research proposal”
- > 27 August 2021 – “Research data management planning: where to start?”

Objectives of EATRIS Horizon funding webinars



- > Capacity- building programme for EATRIS members, targeting researchers and grants officers
- > Focusing on key success factors for funding: innovation and exploitation, open science, responsible research, etc.
- > Particularly relevant for the upcoming Horizon Europe programme and applicable to any research funding strategy.
- > Are there topics you are particularly interested in? Tell us in the chat!

Translational research - the long road from publication to patient





Who we are



To accelerate the translation of research into patient benefit.

We support academia, industry, patients and policy makers.

Our Community

eatris



EATRIS countries

Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Luxembourg, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden



114

Research Institutes



5 Scientific Platforms

- ATMPs
- Biomarker
- Imaging & Tracing
- Small Molecules
- Vaccine, inflammation and immune monitoring



Legal status

Non-profit, ERIC legal status

Examples of key actions



What do we do



1

User access research and expert services

2

Develop new research tools

3

Provide education and training

4


Improve translational ecosystem

The Bricks and Brains



ADVANCED THERAPY MEDICINAL PRODUCTS

Tissue engineering,
Gene therapy, Cell
therapy, GMP
facilities



BIOMARKERS

Biobank facilities,
Multiplexed
immunostaining,
Deep genome
sequencing



IMAGING AND TRACING

(pre-clinical) PET
imaging, GMP
tracer development
and production,
(Ultra) high field
MRI, Optical and
hybrid imaging



SMALL MOLECULES

Advanced
screening (also in
3D cultures),
Development of
xenograft and *in*
 vivo models, Drug
(re-)formulation,
(Pre-)clinical
validation
nanomedicines



VACCINE, INFLAMMATION AND IMMUNE MONITORING

Antigen
characterisation,
Vaccine
formulation,
Process
development



What we offer

How can EATRIS help you?



Access to R&D
EXPERTISE



**VALIDATED TOOLS
AND TECHNOLOGY**
that improve the
Translational process



Support academic
INNOVATION

Support for funding applications

EATRIS offers a range of services to help researchers strengthen the translational potential of their research proposals:

1



**FORMING A
CONSORTIUM**

2



**JOINING AS A
PARTNER**

3



**LEADING FLAGSHIP
PROJECTS***

*EATRIS members only

Consortium-building service

EATRIS offers a consortium-building service free of charge to any party to help coordinators identify the right partners for their consortia.

1



FORMING A CONSORTIUM

Simply fill in this [online form](#) and we will get back to you within a few business days with a report on expertise available and contact information of relevant EATRIS institutions.

For calls of high relevance, we have expertise overviews available:


- [the EIC Pathfinder Challenge on Gene and Cell Therapy](#)
- [the EIC Pathfinder Challenge Tools to measure and stimulate activity in brain tissue](#)

Strengthen your research proposal

EATRIS can participate in research funding proposals as a full partner with affiliated entities providing various services:



- Regulatory support
- HTA
- Translational assessment



- Innovation management
- Industry partnering
- Sustainability



- Education and Training

Joining as a partner

EATRIS can participate in research funding proposals as a full partner with affiliated entities providing various services:

2



**JOINING AS A
PARTNER**

Before joining any proposal, EATRIS scientific team assesses the **translational potential of the project** (regulatory and IP strategy, unmet medical need, etc.).

If you would like us to consider joining your consortium, please send the latest draft of your proposal (or a 3-pager including the composition of the consortium, a summary of the concept and foreseen impact) or fill in [this template](#).

EATRIS training resources are particularly relevant for **MSCA proposals**.

EATRIS can provide in-person workshops, tailor-made to the needs of your project, for example on:

- How to assess the translational potential of your project;
- How to develop collaboration with industry or;
- An introduction to translational medicine (particularly relevant for PhD students and postdocs). For more information, we invite you to [download our workshops leaflet on our dedicated webpage](#).

eatris

**Open
e-learning
platform**



transmed academy

Launched in October 2019

Free online course on the
landscape of translational
medicine

Webinars: Neuro-imaging;
Reproducibility in drug
development

e-learning.transmedacademy.eu

EATRIS' Funding opportunities page for members



SharePoint

eatris

EATRIS Product Platforms

Private group

Home

ATMP

Biomarkers

Shared with us

Imaging & Tracing

Small Molecules

Vaccines

List Service Requests

Events

Disease Working Groups

Digital Resources

Communities homepage

Surveys homepage

User Guide for EATRIS Sh...

FioCruz - EATRIS partners...

Recycle bin

Edit

+ New

Edit in grid view

Share

Export

Automate

Integrate

...

List of funding opportunities

Funding programme

Call

Topic

Scope/challenges

Deadline

Status

Eligibility

Funding per prop...

More information

EATRIS institutions expertise

Horizon Europe - Health Cluster	HORIZON-HLTH-STAYHLTH-2021-01-02	Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patient	- Provide new evidences, methodologies and tools for understanding the transition from health to disease. - Advance the molecular and neurobiological understanding of the interaction of genetic, epigenetic and environmental risk and resilience factors to drive or	21/09/2021	Opening soon	All EU countries, EU Associated countries	10 M	- Multiomics technologies (Genomics: NGS, deep ge sequencing, Mass spectrometry for multi-omic anal Biomarkers expertise, Imaging capabilities, samples/ cohorts, Disease experts. - In silico platforms to predict novel drug targets (s
Horizon Europe - Health Cluster	HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage	Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression	Artificial intelligence along with the increased availability of health data hold great potential to pave the way for personalised prevention and enable progress towards risk prediction and early detection of	01/02/2022	Announced	All EU countries, EU Associated countries	6 M	- Regulatory expertise - Network of over 50 academic medical research centres with translational capacities to support validation of AI tools. - Translational imaging data to support radiomics approaches
Horizon Europe - Health Cluster	HORIZON-HLTH-2021-DISEASE-04-02				Opening soon	All EU countries, EU Associated countries	25 M	- Chemosensitivity screening in using existing drugs/ patient materials - In silico/ systems biology approaches to support repurposing campaigns - Drug re-formulation expertise
Horizon Europe - Health Cluster	HORIZON-HLTH-DISEASE-2021-04-07				Opening soon	All EU countries, EU Associated countries	7 M	- Multiomics technologies (Genomics: NGS, deep ge sequencing, Mass spectrometry for multi-omic anal Expertise in Biomarkers (Discovery, validation, assay Samples/data cohorts, Preclinical models, Quality in Innovation Management,
Horizon Europe - Health Cluster	HORIZON-HLTH-2022-DISEASE-06-02-two-stage				Announced	All EU countries, EU Associated countries	6 M	- Preclinical development and study of new immunotherapeutic agents in vitro and in relevant disease models - Preclinical and clinical Immune profiling, immune monitoring
Horizon Europe - Health Cluster	HORIZON-HLTH-2022-DISEASE-...	Vaccines 2.0 - developing the next generation of vaccines	This collaborative research and innovation action aims to diversify and accelerate the global vaccine R&D pipeline, and to strengthen the current leading role of EU in technological development and vaccine research & innovation.	01/02/2022	Announced	All EU countries, EU Associated countries	8 M	- Bsl3 facilities - Adjuvant development - Preclinical and clinical Immune profiling, immune monitoring - Cell tracking and various non-invasive imaging
Horizon Europe - Health Cluster	HORIZON-HLTH-TOOL-2021-06-02	Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet needs	- Ensure that the next wave of advanced therapies, based on either pluripotent stem cells, gene editing or RNA, are established in a timely fashion and in accordance with the appropriate regulatory standards	21/09/2021	Opening soon	All EU countries, EU Associated countries	6 M	- Expertise in cell therapy and genome editing prod targeted cells and tissues (e.g., base editing, prime editing, zinc-finger nucleases, CRISPR). - Expertise in novel RNA-based therapeutics

Launch June 22nd 2021

when Horizon Europe Work programmes are officially published.

Resources at your disposal

- ✓ **Comprehensive funding opportunities database** for all members is ready for launch and will be updated monthly (accessible at any time via EATRIS Communities site)
- ✓ **EATRIS monthly (monthly update for EATRIS members)**
Featuring funding calls for translational research
- ✓ **Dedicated webpage**
<https://eatris.eu/services/support-for-funding-applications/>
- ✓ **Leaflet for general services**



Business development to bring our members opportunities to join consortia

eatris

- ✓ **Membership to Crowdhelix since February 2021**

<https://www.crowdhelix.com/>



- ✓ **Active outreach** to funding consultancy companies to showcase consortium-building services



ZAZ VENTURES
DEEP TECH INNOVATION. FUNDED



Catalyze



TTOPSTART

- ✓ Participation in **brokerage events**

Your contacts at EATRIS



Anne-Charlotte Fauvel, Head of European Affairs
annecharlottefauvel@eatris.eu



Camilla Santinelli, Grants Administrator
camillasantinelli@eatris.eu



Your country's national director or national coordinator
See: <https://eatris.eu/people/>

They support EATRIS



Czech Republic
Ministry of Education,
Youth and Sports (MEYS)



Republic of Finland
Ministry of Education and Culture
(OKM)



French Republic
Commissariat à l'Energie Atomique et
aux Energies Alternatives (CEA)



Italian Republic
Istituto Superiore di Sanità (ISS)



Kingdom of Luxembourg
Le Gouvernement du grand-duché de
Luxembourg



Kingdom of the Netherlands
ZonMW



Kingdom of Norway
Research Council of Norway*



Republic of Portugal
INFARMED-National Authority of
Medicines and Health Products




Republic of Slovenia
Ministry of Education, Science
and Sport



Kingdom of Spain
Instituto de Salud 'Carlos III' (ISCIII)



Republic of Bulgaria
Ministry of Education and Science



Kingdom of Sweden
Vetenskapsrådet



Republic of Croatia
Ministry of Science and Education



Republic of Latvia
Ministry of Education and Science

* The contribution in Norway is shared between University of Oslo (UiO), University of Bergen (UiB), Norwegian University of Science and Technology (NTNU), the Arctic University of Norway (UiT) and the four Regional Health Authorities in Southeastern, Western, Central and Northern Norway

Next EATRIS Horizon funding webinars



- > 25 June 2021 – “Optimising the innovation and exploitation strategies of your research proposal”
- > 27 August 2021 – “Research data management planning: where to start?”

Stay in contact



EATRIS



@EatrisEric



www.eatris.eu



EATRIS Monthly
Translational Trends

